Terms: = Prostate cancer AND FOXP1, MGC12942, 27086, ENSG00000114861, hFKH1B, MGC99551, FLJ23741, QRF1, 12CC4, HSPC215, MGC88572 AND Prognosis
5 results:
1. Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets.
Spethmann T; Böckelmann LC; Labitzky V; Ahlers AK; Schröder-Schwarz J; Bonk S; Simon R; Sauter G; Huland H; Kypta R; Schumacher U; Lange T
Mol Oncol; 2021 Jul; 15(7):1956-1969. PubMed ID: 33533127
[TBL] [Abstract] [Full Text] [Related]
2. Deletion of 3p13-14 locus spanning foxp1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis.
Hieronymus H; Iaquinta PJ; Wongvipat J; Gopalan A; Murali R; Mao N; Carver BS; Sawyers CL
Nat Commun; 2017 Oct; 8(1):1081. PubMed ID: 29057879
[TBL] [Abstract] [Full Text] [Related]
3. Identification of Novel Epigenetic Markers of prostate cancer by NotI-Microarray Analysis.
Dmitriev AA; Rosenberg EE; Krasnov GS; Gerashchenko GV; Gordiyuk VV; Pavlova TV; Kudryavtseva AV; Beniaminov AD; Belova AA; Bondarenko YN; Danilets RO; Glukhov AI; Kondratov AG; Alexeyenko A; Alekseev BY; Klein G; Senchenko VN; Kashuba VI
Dis Markers; 2015; 2015():241301. PubMed ID: 26491211
[TBL] [Abstract] [Full Text] [Related]
4. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
[TBL] [Abstract] [Full Text] [Related]
5. cancer genetics and genomics of human FOX family genes.
Katoh M; Igarashi M; Fukuda H; Nakagama H; Katoh M
Cancer Lett; 2013 Jan; 328(2):198-206. PubMed ID: 23022474
[TBL] [Abstract] [Full Text] [Related]